Avidity Biosciences - Stock Price History | RNA

Historical daily share price chart and data for Avidity Biosciences since 2021 adjusted for splits. The latest closing stock price for Avidity Biosciences as of September 27, 2021 is 23.29.
  • The all-time high Avidity Biosciences stock closing price was 35.94 on September 14, 2020.
  • The Avidity Biosciences 52-week high stock price is 36.02, which is 54.7% above the current share price.
  • The Avidity Biosciences 52-week low stock price is 17.58, which is 24.5% below the current share price.
  • The average Avidity Biosciences stock price for the last 52 weeks is 24.69.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Avidity Biosciences Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 29.0006 31.4000 35.9400 23.3500 25.5200 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.877B $0.007B
Avidity Biosciences Inc. is a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates(TM). The company's AOC platform design, engineer and develop therapeutics which combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies. Its lead product candidate consist AOC 1001, is designed to treat myotonic dystrophy type 1,and other muscle programs are focused on the treatment of muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy and Pompe disease. Avidity Biosciences Inc. is based in SAN DIEGO.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $132.971B 8.85
Bio-Rad Laboratories (BIO.B) United States $22.624B 48.22
QIAGEN (QGEN) Netherlands $12.001B 20.32
Biohaven Pharmaceutical Holding (BHVN) United States $8.691B 0.00
Emergent Biosolutions (EBS) United States $2.870B 6.92
Arcus Biosciences (RCUS) United States $2.690B 0.00
Myovant Sciences (MYOV) United Kingdom $2.182B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.045B 0.00
Zymeworks (ZYME) Canada $1.373B 0.00
Ambrx Biopharma (AMAM) United States $0.501B 0.00
SQZ Biotechnologies (SQZ) United States $0.442B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29